The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans-Reference-Cited by-同舟云学术

The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans

Published:2020-01 Issue: Volume:162 Page:107809
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Varnäs Katarina,Cselényi Zsolt,Arakawa Ryosuke,Nag Sangram,Stepanov Vladimir,Moein Mohammad Mahdi,Johnström Peter,Kingston Lee,Elmore Charles S.,Halldin Christer,Farde Lars

Funder

Swedish Research Council

AstraZeneca

GE Healthcare

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference54 articles.

1. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688;Ametamey;J. Nucl. Med.,2007

2. Palladium mediated 11C-cyanation and characterization in the non-human primate brain of the novel mGluR5 radioligand [11C]AZD9272;Andersson;Nucl. Med. Biol.,2013

3. Test-retest reproducibility of [11C]-L-deprenyl-D2 binding to MAO-B in the human brain;Arakawa;EJNMMI Res.,2017

4. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity;Cosford;J. Med. Chem.,2003

5. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited;Cunningham;J. Cereb. Blood Flow Metab.,2010

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ANXIOLYTICS: Origins, drug discovery, and mechanisms;Pharmacology Biochemistry and Behavior;2024-12

2. PET imaging of neuroinflammation: any credible alternatives to TSPO yet?;Molecular Psychiatry;2024-07-13

3. PET Evaluation of the Novel F-18 Labeled Reversible Radioligand [¹⁸F]GEH200449 for Detection of Monoamine Oxidase-B in the Non-Human Primate Brain;ACS Chemical Neuroscience;2023-08-17

4. Clinical investigations of compounds targeting metabotropic glutamate receptors;Pharmacology Biochemistry and Behavior;2022-09

5. Group I mGluRs in Therapy and Diagnosis of Parkinson’s Disease: Focus on mGluR5 Subtype;Biomedicines;2022-04-07